首页 > 市场调查报告书 > 医疗设备

生技设备基因治疗学和RNAi

市场调查报告书

商品编码

1532593

无标籤阵列系统市场 - 按技术、应用、最终用途 - 全球预测

Label-free Array Systems Market - By Technology, Application, End-use - Global Forecast

出版日期: 2024年05月27日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在即时照护 (POC) 诊断热潮的推动下，全球无标籤阵列系统市场从 2024 年到 2032 年的复合年增长率将超过 7.2%。随着医疗保健专业人员寻求无需复杂的样品製备或标记即可提供即时分析的解决方案，对快速、准确和用户友好的诊断工具的需求不断增加。对现场诊断的需求推动了这一趋势，现场诊断可以提供即时结果并促进及时决策。

无标籤阵列系统提供增强的诊断功能，支援更广泛地采用即时侦测。举个例子，2024年1月，HORIBA Medical推出了HELO 2.0高通量自动化血液学平台，现已获得CE-IVDR批准，正在等待美国FDA批准。此新系统为大中型实验室提供灵活的模组化配置，整合先进技术以提高效率和更环保的操作。

无标记阵列系统市场根据技术、应用、最终用途和地区进行细分。

由于对高解析度分子交互作用和即时分析能力的需求不断增加，生物层干涉测量领域将在 2024 年至 2032 年间呈现出值得注意的复合年增长率。随着生命科学研发的进步，人们越来越重视取得精确的、无标记的资料，以便更了解生物分子过程。这种转变是由于对复杂生物测定中更准确和可重复结果的渴望所驱动的，从而导致更多地采用无需额外标记步骤即可提供直接和详细测量的技术。

到 2032 年，由于对蛋白质动力学了解的需求不断增长，蛋白质界面分析领域将占据相当大的无标记阵列系统市场份额。研究人员和製药公司致力于阐明复杂的蛋白质行为和相互作用，以推进药物发现和开发。无标记技术提供了一种非侵入性、即时的方法来研究这些相互作用，在不受额外标记试剂干扰的情况下提供有价值的见解。这种以高精度和分辨率直接分析蛋白质界面的能力正在推动无标记系统的采用。

到 2032 年，由于对生命科学研究的投资和对技术创新的高度重视，北美无标籤阵列系统市场将呈现出令人印象深刻的复合年增长率。研究机构和生技公司正在引领分子生物学的进步，需要先进的分析工具来实现高效率的资料收集。对个人化医疗和基因组学研究的日益重视，增强了对提供即时结果的无标籤技术的需求。政府资助和协作研究环境支持北美地区不断增长的产品采用，有利于市场成长。

产业生态系统分析
产业影响力
- 成长动力
  - 增加药物发现和开发活动
  - 生物技术与生命科学研究的进步
  - 慢性病和传染病病例不断增加
- 产业陷阱与挑战
  - 初期投资成本高
  - 复杂性和技术专长要求
成长潜力分析
技术景观
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
竞争定位矩阵
战略展望矩阵

第 5 章：市场估计与预测：按技术分类，2021 - 2032 年

主要趋势
表面等离子共振
生物层干涉测量
细胞介电谱
微悬臂梁
扫描开尔文奈米探针
焓阵
原子力显微镜
其他技术

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
药物发现
蛋白质界面分析
抗体表征和开发
蛋白质复合物和级联分析
疾病生物标记检测
其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
製药和生物技术公司
学术及研究机构
合约研究组织
医院和诊所
其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Agilent Technologies, Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Corning Incorporated
Danaher Corporation
F. Hoffmann-La Roche AG
Illumina, Inc.
Merck KGaA
Meso Scale Diagnostics (MSD)
Nanion Technologies
Pall Corporation
PerkinElmer, Inc.
Sartorius AG
Siemens Healthineers AG
Thermo Fisher Scientific Inc.

简介目录

Product Code: 9649

Global Label-free Array Systems Market will register over 7.2% CAGR from 2024 to 2032, driven by the upsurge of point-of-care (POC) diagnostics. The demand for rapid, accurate, and user-friendly diagnostic tools is increasing as healthcare professionals seek solutions that offer real-time analysis without complex sample preparation or labeling. This trend is fueled by the need for on-the-spot diagnostics that provide immediate results and facilitate timely decision-making.

Label-free array systems offer enhanced diagnostic capabilities, supporting the broader adoption of point-of-care testing. Quoting an instance, in January 2024, HORIBA Medical launched the HELO 2.0 high-throughput automated hematology platform, now CE-IVDR approved and pending US FDA clearance. This new system offers flexible, modular configurations for mid to large-scale labs, integrating advanced technologies for improved efficiency and eco-friendlier operation.

The label-free array systems market is segmented based on technology, application, end-use, and region.

The bio-layer interferometry segment will evince a noteworthy CAGR between 2024 and 2032, due to the increasing need for high-resolution molecular interactions and real-time analytical capabilities. As R&D in life sciences advances, there is a growing emphasis on obtaining precise, label-free data to better understand biomolecular processes. The shift is driven by the desire for more accurate and reproducible results in complex biological assays, leading to higher adoption of technologies that offer direct and detailed measurement without the need for additional labeling steps.

By 2032, the protein interface analysis segment will grab a sizeable label-free array systems market share, attributed to the growing need for an understanding of protein dynamics. Researchers and pharmaceutical companies are focused on elucidating complex protein behaviors and interactions to advance drug discovery and development. Label-free technologies offer a non-invasive, real-time approach to studying these interactions, providing valuable insights without the interference of additional labeling agents. This ability to directly analyze protein interfaces with high accuracy and resolution is thriving the adoption of label-free systems.

Through 2032, North America label-free array systems market will show an impressive CAGR, due to investments in life sciences research and a strong focus on technological innovation. The research institutions and biotechnology companies are leading advancements in molecular biology, requiring advanced analytical tools for efficient data acquisition. The increasing emphasis on personalized medicine and genomics research is strengthening the need for label-free technologies that deliver real-time results. Government funding and a collaborative research environment support the growing product adoption across North America, favoring market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing drug discovery and development activities
  - 3.2.1.2 Advancements in biotechnology and life sciences research
  - 3.2.1.3 Rising cases of chronic and infectious diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High initial investment cost
  - 3.2.2.2 Complexity and technical expertise requirements
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Surface plasmon resonance
5.3 Bio-layer interferometry
5.4 Cellular dielectric spectroscopy
5.5 Microcantilever
5.6 Scanning kelvin nanoprobe
5.7 Enthalpy array
5.8 Atomic force microscopy
5.9 Other technologies

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Drug discovery
6.3 Protein interface analysis
6.4 Antibody characterization and development
6.5 Protein complex and cascade analysis
6.6 Detection of disease biomarkers
6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pharmaceutical & biotechnology companies
7.3 Academic & research institutes
7.4 Contract research organizations
7.5 Hospitals and clinics
7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa